Abstract:
Aim: “Ischemia modified albumin” (IMA) was investigated as a possible biomarker in several diseases such as vascular disorders.
We aimed to reveal the possible value of IMA in predicting the development of contrast induced nephropathy (CIN) after coronary
angiography in patients with stable angina pectoris.
Material and Methods: 106 patients underwent coronary angiography with a diagnosis of stable angina pectoris were included
in our study. Basic demographic and clinical findings and laboratory values were recorded and analyzed. Serum creatinine (SCre)
levels were also measured 48 hours after coronary angiography and recorded. Amount of contrast agent (CA) given during coronary
angiography was recorded. The patients were divided into 2 groups: CIN positive and CIN negative groups.
Results: CIN was developed in 14 patients (13%); and IMA levels were similar in CIN positive and negative groups (p>0.05). SCre
(both measurements before and after CA administration) was not correlated with IMA levels. There was no association between drug
usage and development of CIN (p>0.05). Comorbidities were not associated with the development of CIN (p>0.05) with the exception
of hypertension (HT). Presence of hypertension (p=0.0393) and female gender (p=0.0199) was associated with development of CIN.
Mean age was 61.3 and 52.3 in CIN positive and negative groups, respectively (p>0.05).
Conclusion: Any specific biomarker indicating CIN is not available yet. Most frequently used marker is the measurement of SCre 24-
48 hours after administration of CA. We found IMA levels not to be a predictor for the development of CIN. Further investigations will
clearly determine the importance of IMA as a biomarker in renal failure developed after CA administration.
